Equities Analysts Offer Predictions for TLSI FY2026 Earnings

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) – Analysts at Northland Capmk increased their FY2026 earnings per share (EPS) estimates for shares of TriSalus Life Sciences in a research note issued to investors on Tuesday, November 26th. Northland Capmk analyst C. Byrnes now expects that the company will earn ($0.60) per share for the year, up from their previous forecast of ($0.75). Northland Capmk has a “Strong-Buy” rating on the stock. The consensus estimate for TriSalus Life Sciences’ current full-year earnings is ($1.55) per share.

TLSI has been the topic of a number of other reports. Roth Capital upgraded shares of TriSalus Life Sciences to a “strong-buy” rating in a report on Monday, November 11th. Canaccord Genuity Group reduced their target price on TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating on the stock in a report on Friday, November 15th. Northland Securities initiated coverage on TriSalus Life Sciences in a research note on Friday, October 25th. They set an “outperform” rating and a $12.50 price target for the company. Oppenheimer started coverage on TriSalus Life Sciences in a report on Monday, September 16th. They set an “outperform” rating and a $10.00 price target for the company. Finally, Roth Mkm began coverage on TriSalus Life Sciences in a report on Monday, November 11th. They set a “buy” rating and a $11.00 price objective on the stock. Six equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, TriSalus Life Sciences currently has a consensus rating of “Buy” and an average target price of $12.08.

TriSalus Life Sciences Stock Performance

TLSI stock opened at $4.25 on Thursday. The company’s fifty day moving average price is $4.22 and its 200-day moving average price is $5.47. TriSalus Life Sciences has a one year low of $3.61 and a one year high of $10.42. The company has a market capitalization of $129.58 million, a PE ratio of -1.71 and a beta of 0.49.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Walleye Capital LLC purchased a new position in shares of TriSalus Life Sciences during the 3rd quarter worth about $66,000. Virtu Financial LLC bought a new stake in TriSalus Life Sciences in the third quarter worth about $92,000. Vestcor Inc purchased a new position in shares of TriSalus Life Sciences during the third quarter valued at approximately $108,000. MSD Partners L.P. bought a new position in shares of TriSalus Life Sciences during the third quarter valued at approximately $184,000. Finally, Wolverine Asset Management LLC purchased a new stake in shares of TriSalus Life Sciences in the second quarter worth approximately $240,000. Institutional investors own 2.58% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Mary T. Szela purchased 7,520 shares of the stock in a transaction that occurred on Thursday, September 12th. The stock was bought at an average cost of $5.20 per share, for a total transaction of $39,104.00. Following the completion of the transaction, the chief executive officer now directly owns 377,382 shares in the company, valued at $1,962,386.40. This represents a 2.03 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders have purchased 19,560 shares of company stock valued at $95,190 over the last ninety days. 32.80% of the stock is owned by insiders.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.